We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases

Press releases

Novasep and instrAction expand alliance to include taxane purification - (2/7/2011)

07 Feb 2011

Companies will develop solutions to change manufacturing paradigm for new and generic anti-cancer compounds. Joint technical showcase presentation at Informex, Charlotte, NC, USA, Feb 7, Booth: 1987

Novasep and Danisco announce the first betaine industrial production process from bioethanol side-stream - (12/15/2010)

15 Dec 2010

Joint project will offer a cost-effective, environmentally friendly process to produce betaine, an animal feed ingredient in short supply.

Novasep Process and Nutritis announce the scale-up of the production process for Nutritis’ fructose purification from substandard fruit - (11/9/2010)

09 Nov 2010

Novasep’s role in scaling up this patented process helped Nutritis close a EUR 13.5M financing round and acquire a fructose unit exclusively for fruit processing.

Novasep and Mega sign a strategic technology partnership to develop whey treatment solutions for the dairy industry - (11/5/2010)

05 Nov 2010

Electrodialysis and manufacturing process companies come together to design the most cost-effective whey demineralization solutions offering guaranteed performance.

Novasep appoints a new Chairman for its Supervisory Board - Bernard Dubois, former Aventis Senior VP of Global Industrial Operations - (9/1/2010)

01 Sep 2010

Novasep appoints a new Chairman for its Supervisory Board Bernard Dubois, former Aventis Senior VP of Global Industrial Operations brings a wealth of experience to Novasep’s top management team.

Cerenis Therapeutics and Novasep awarded EUR 10.7 million funding from the French Government for the development CER-001, an HDL mimetic - (7/26/2010)

26 Jul 2010

July 26, 2010 - Toulouse and Pompey, France: Cerenis Therapeutics SA (Cerenis), a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and other metabolic diseases, and Groupe Novasep (Novasep), a leading supplier of manufacturing solutions to the life sciences industries, announce today that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic.

Novasep and instrAction enter into a worldwide strategic alliance for non-chiral chromatography - (7/19/2010)

19 Jul 2010

Combination of instrAction and Novasep know-how sets a new standard for small molecule purification processes for the life science industries.

Novasep appoints two key executives - (5/3/2010)

03 May 2010

Stephen Stefano heads up Novasep North American business and PatrickGlaser leads Novasep Synthesis division.

Provepharm announces acceptance of Proveblue® injectable drug MAA for review under EMEA centralized procedure and validation by Novasep of API cGMP process - (2/11/2010)

11 Feb 2010

Provepharm’s methylthioninium chloride “Proveblue®” dramatically decreases risk posed by dangerous impurities in methylene blue and opens way for use in applications including methemoglobinemia, urinary infections and malaria.

You can stay on this page and select more documents or you can directly download the brochure(s) you selected
Give us your feedback!